Found: 69
Select item for more details and to access through your institution.
Identification and Characterisation of Infiltrating Immune Cells in Malignant Pleural Mesothelioma Using Spatial Transcriptomics.
- Published in:
- Methods & Protocols, 2023, v. 6, n. 2, p. 35, doi. 10.3390/mps6020035
- By:
- Publication type:
- Article
Cutaneous Toxic Effects of BRAF Inhibitors Alone and in Combination With MEK Inhibitors for Metastatic Melanoma.
- Published in:
- 2015
- By:
- Publication type:
- journal article
The molecular and functional landscape of resistance to immune checkpoint blockade in melanoma.
- Published in:
- Nature Communications, 2023, v. 14, n. 1, p. 1, doi. 10.1038/s41467-023-36979-y
- By:
- Publication type:
- Article
Immune Checkpoint Inhibitor Toxicity.
- Published in:
- Current Oncology Reports, 2018, v. 20, n. 9, p. 1, doi. 10.1007/s11912-018-0718-6
- By:
- Publication type:
- Article
Checkpoint Inhibitor-Associated Autoimmune Diabetes Mellitus Is Characterized by C-peptide Loss and Pancreatic Atrophy.
- Published in:
- Journal of Clinical Endocrinology & Metabolism, 2024, v. 109, n. 5, p. 1301, doi. 10.1210/clinem/dgad685
- By:
- Publication type:
- Article
Association of Antithyroid Antibodies in Checkpoint Inhibitor–Associated Thyroid Immune–Related Adverse Events.
- Published in:
- Journal of Clinical Endocrinology & Metabolism, 2022, v. 107, n. 5, p. 1843, doi. 10.1210/clinem/dgac059
- By:
- Publication type:
- Article
Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Immune checkpoint inhibitor‐induced lichenoid drug eruption‐sparing scar burns.
- Published in:
- Australasian Journal of Dermatology, 2024, v. 65, n. 2, p. 163, doi. 10.1111/ajd.14192
- By:
- Publication type:
- Article
Lichen sclerosus and immune checkpoint inhibitors: A case and review of the literature.
- Published in:
- Australasian Journal of Dermatology, 2023, v. 64, n. 1, p. 158, doi. 10.1111/ajd.13941
- By:
- Publication type:
- Article
Clinicopathological characteristics of new primary melanomas in patients receiving immune checkpoint inhibitor therapy for metastatic melanoma.
- Published in:
- Australasian Journal of Dermatology, 2022, v. 63, n. 2, p. e133, doi. 10.1111/ajd.13807
- By:
- Publication type:
- Article
ASO Visual Abstract: Survival Outcomes of Salvage Metastasectomy after Failure of Modern-Era Systemic Therapy for Melanoma.
- Published in:
- 2021
- By:
- Publication type:
- Abstract
Survival Outcomes of Salvage Metastasectomy After Failure of Modern-Era Systemic Therapy for Melanoma.
- Published in:
- Annals of Surgical Oncology: An Oncology Journal for Surgeons, 2021, v. 28, n. 11, p. 6109, doi. 10.1245/s10434-021-10489-x
- By:
- Publication type:
- Article
Immunotherapy in advanced Merkel cell carcinoma: Sydney west cancer network experience.
- Published in:
- Journal of Medical Imaging & Radiation Oncology, 2021, v. 65, n. 6, p. 760, doi. 10.1111/1754-9485.13243
- By:
- Publication type:
- Article
Radiological manifestations of immune-related adverse effects observed in patients with melanoma undergoing immunotherapy.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Cross-platform comparison of immune signatures in immunotherapy-treated patients with advanced melanoma using a rank-based scoring approach.
- Published in:
- Journal of Translational Medicine, 2023, v. 21, n. 1, p. 1, doi. 10.1186/s12967-023-04092-9
- By:
- Publication type:
- Article
Optimizing combination dabrafenib and trametinib therapy in BRAF mutation-positive advanced melanoma patients: Guidelines from Australian melanoma medical oncologists.
- Published in:
- Asia Pacific Journal of Clinical Oncology, 2016, v. 12, p. 5, doi. 10.1111/ajco.12656
- By:
- Publication type:
- Article
Evaluation of two high-throughput proteomic technologies for plasma biomarker discovery in immunotherapy-treated melanoma patients.
- Published in:
- Biomarker Research, 2017, v. 5, p. 1, doi. 10.1186/s40364-017-0112-9
- By:
- Publication type:
- Article
Clinical significance of intronic variants in BRAF inhibitor resistant melanomas with altered BRAF transcript splicing.
- Published in:
- Biomarker Research, 2017, v. 5, p. 1, doi. 10.1186/s40364-017-0098-3
- By:
- Publication type:
- Article
Inter- and Intra-Patient Heterogeneity of Response and Progression to Targeted Therapy in Metastatic Melanoma.
- Published in:
- PLoS ONE, 2014, v. 9, n. 1, p. 1, doi. 10.1371/journal.pone.0085004
- By:
- Publication type:
- Article
Musculoskeletal immune‐related adverse events with the use of checkpoint inhibitors in malignancy.
- Published in:
- Internal Medicine Journal, 2022, v. 52, n. 5, p. 818, doi. 10.1111/imj.15123
- By:
- Publication type:
- Article
Pretreatment Innate Cell Populations and CD4 T Cells in Blood Are Associated With Response to Immune Checkpoint Blockade in Melanoma Patients.
- Published in:
- Frontiers in Immunology, 2020, p. 1, doi. 10.3389/fimmu.2020.00372
- By:
- Publication type:
- Article
VEGF Inhibitors Improve Survival Outcomes in Patients with Liver Metastases across Cancer Types—A Meta-Analysis.
- Published in:
- Cancers, 2023, v. 15, n. 20, p. 5012, doi. 10.3390/cancers15205012
- By:
- Publication type:
- Article
Immune-Checkpoint Inhibitors for Metastatic Colorectal Cancer: A Systematic Review of Clinical Outcomes.
- Published in:
- Cancers, 2021, v. 13, n. 17, p. 4345, doi. 10.3390/cancers13174345
- By:
- Publication type:
- Article
Clinical and Molecular Heterogeneity in Patients with Innate Resistance to Anti-PD-1 +/− Anti-CTLA-4 Immunotherapy in Metastatic Melanoma Reveals Distinct Therapeutic Targets.
- Published in:
- Cancers, 2021, v. 13, n. 13, p. 3186, doi. 10.3390/cancers13133186
- By:
- Publication type:
- Article
Circulating Tumor DNA Reflects Uveal Melanoma Responses to Protein Kinase C Inhibition.
- Published in:
- Cancers, 2021, v. 13, n. 7, p. 1740, doi. 10.3390/cancers13071740
- By:
- Publication type:
- Article
Tumor MHC Expression Guides First-Line Immunotherapy Selection in Melanoma.
- Published in:
- Cancers, 2020, v. 12, n. 11, p. 3374, doi. 10.3390/cancers12113374
- By:
- Publication type:
- Article
Design and Testing of a Custom Melanoma Next Generation Sequencing Panel for Analysis of Circulating Tumor DNA.
- Published in:
- Cancers, 2020, v. 12, n. 8, p. 2228, doi. 10.3390/cancers12082228
- By:
- Publication type:
- Article
Analysis of the Whole-Exome Sequencing of Tumor and Circulating Tumor DNA in Metastatic Melanoma.
- Published in:
- Cancers, 2019, v. 11, n. 12, p. 1905, doi. 10.3390/cancers11121905
- By:
- Publication type:
- Article
ASO Visual Abstract: Role of Concurrent Ultrasound Surveillance of Sentinel Node-Positive Node Fields in Melanoma Patients Having Routine Cross-Sectional Imaging.
- Published in:
- 2024
- By:
- Publication type:
- Abstract
Role of Concurrent Ultrasound Surveillance of Sentinel Node-Positive Node Fields in Melanoma Patients Having Routine Cross-Sectional Imaging.
- Published in:
- Annals of Surgical Oncology: An Oncology Journal for Surgeons, 2024, v. 31, n. 3, p. 1857, doi. 10.1245/s10434-023-14526-9
- By:
- Publication type:
- Article
Extended Follow-Up of Chronic Immune-Related Adverse Events Following Adjuvant Anti–PD-1 Therapy for High-Risk Resected Melanoma.
- Published in:
- JAMA Network Open, 2023, v. 6, n. 8, p. e2327145, doi. 10.1001/jamanetworkopen.2023.27145
- By:
- Publication type:
- Article
Telehealth follow‐up consultations for melanoma patients during the COVID‐19 pandemic: Patient and clinician satisfaction.
- Published in:
- Cancer Medicine, 2023, v. 12, n. 23, p. 21373, doi. 10.1002/cam4.6679
- By:
- Publication type:
- Article
Five‐year survival and clinical correlates among patients with advanced non‐small cell lung cancer, melanoma and renal cell carcinoma treated with immune check‐point inhibitors in Australian tertiary oncology centres.
- Published in:
- Cancer Medicine, 2023, v. 12, n. 6, p. 6788, doi. 10.1002/cam4.5468
- By:
- Publication type:
- Article
Grade 4 Neutropenia Secondary to Immune Checkpoint Inhibition — A Descriptive Observational Retrospective Multicenter Analysis.
- Published in:
- Frontiers in Oncology, 2021, v. 11, p. 1, doi. 10.3389/fonc.2021.765608
- By:
- Publication type:
- Article
Unravelling Checkpoint Inhibitor Associated Autoimmune Diabetes: From Bench to Bedside.
- Published in:
- Frontiers in Endocrinology, 2021, v. 12, p. 1, doi. 10.3389/fendo.2021.764138
- By:
- Publication type:
- Article
Adjuvant immunotherapy recommendations for stage III melanoma: physician and nurse interviews.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Risk of radiation necrosis after stereotactic radiosurgery for melanoma brain metastasis by anatomical location.
- Published in:
- Strahlentherapie und Onkologie, 2021, v. 197, n. 12, p. 1104, doi. 10.1007/s00066-021-01798-x
- By:
- Publication type:
- Article
Hypermethylation of Circulating Free DNA in Cutaneous Melanoma.
- Published in:
- Applied Sciences (2076-3417), 2019, v. 9, n. 23, p. 5074, doi. 10.3390/app9235074
- By:
- Publication type:
- Article
PDCD1 Polymorphisms May Predict Response to Anti-PD-1 Blockade in Patients With Metastatic Melanoma.
- Published in:
- Frontiers in Immunology, 2021, v. 12, p. 1, doi. 10.3389/fimmu.2021.672521
- By:
- Publication type:
- Article
Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma.
- Published in:
- Nature Communications, 2014, v. 5, n. 12, p. 5694, doi. 10.1038/ncomms6694
- By:
- Publication type:
- Article
Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Reply to 'Comment on 'Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy''.
- Published in:
- 2017
- By:
- Publication type:
- Letter
Cessation of targeted therapy after a complete response in BRAF-mutant advanced melanoma: a case series.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Clinical and genomic correlates of imatinib response in melanomas with KIT alterations.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Immune checkpoint inhibitor therapy for advanced cutaneous squamous cell carcinoma in Australia: a retrospective real world cohort study.
- Published in:
- Medical Journal of Australia, 2024, v. 220, n. 2, p. 80, doi. 10.5694/mja2.52199
- By:
- Publication type:
- Article
Immunotherapy in advanced cutaneous squamous cell carcinoma: Sydney west cancer network experience.
- Published in:
- ANZ Journal of Surgery, 2023, v. 93, n. 1/2, p. 235, doi. 10.1111/ans.18219
- By:
- Publication type:
- Article
Melanoma management in the 21st century: a change in paradigm.
- Published in:
- ANZ Journal of Surgery, 2021, v. 91, n. 12, p. 2557, doi. 10.1111/ans.17356
- By:
- Publication type:
- Article
Site-specific response patterns, pseudoprogression, and acquired resistance in patients with melanoma treated with ipilimumab combined with anti-PD-1 therapy.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors.
- Published in:
- 2015
- By:
- Publication type:
- journal article
Melanoma medicine: New drugs for melanoma and the role of the general practitioner.
- Published in:
- Australian Journal of General Practice, 2024, v. 53, n. 9, p. 619, doi. 10.31128/ajgp-01-24-7129
- By:
- Publication type:
- Article